Efficacy and Safety of IL-17 and JAK Inhibitors in Ankylosing Spondylitis: A Systematic Review and Network Meta-Analysis

塞库金单抗 医学 托法替尼 伊克泽珠单抗 强直性脊柱炎 安慰剂 内科学 随机对照试验 荟萃分析 银屑病性关节炎 类风湿性关节炎 替代医学 病理
作者
Xiaojuan Zhao,Menghao Li,Xinhui Zhang,Yunfei Tian,Dan Li,Yongjing Wang,Yonghong Zhao,Qianying Li,Y.-F. Qi,Xiuju Liu
出处
期刊:International Archives of Allergy and Immunology [S. Karger AG]
卷期号:: 1-18
标识
DOI:10.1159/000544752
摘要

Objective: The aim of this study was to compare the clinical efficacy and safety of interleukin-17 inhibitors and Janus kinase inhibitors in the treatment of ankylosing spondylitis based on a network meta-analysis. Methods: According to the search strategy, systematic retrievals were conducted in PubMed, Embase, Web of Science, the Cochrane Register of Clinical Trials, Scopus, and website ClinicalTrials.gov, from the establishment to December 8, 2023. Randomized controlled trials (RCTs) of interleukin-17 inhibitors and Janus kinase inhibitors for the treatment of ankylosing spondylitis were selected according to the inclusion and exclusion criteria. The included studies were evaluated for quality using the Cochrane Risk of Bias Assessment Tool, and data were statistically analyzed using Software Stata 16.0, to compare the effectiveness and safety differences in all interventions. Results: A total of 18 RCTs involving 3968 subjects were included in this study. The interventions were ranked from best to worst in terms of ASAS20: netakimab 120 mg > filgotinib 200 mg > tofacitinib 5 mg> brodalumab 210 mg >upadacitinib 15 mg >bimekizumab 160 mg > secukinumab 300 mg> ixekizumab 80 mg Q4W > secukinumab 150 mg > secukinumab 150 mg no LD> placebo, netakimab 120 mg outperformed all other interventions and the difference was statistically significant. The interventions were ranked from best to worst in terms of ASAS40: netakimab 120 mg > tofacitinib 5 mg > secukinumab 150 mg > secukinumab 300 mg > upadacitinib 15 mg > bimekizumab 160 mg> ixekizumab 80 mg Q4W > filgotinib 200 mg > brodalumab 210 mg > secukinumab 150 mg no LD > placebo, netakimab 120 mg outperformed all other interventions and was statistically significant (except the intervention of filgotinib 200 mg). In terms of AEs and SAEs, there was no statistical significance among all interventions. Conclusions: The results of the network meta-analysis showed that netakimab 120mg ranked relatively high in outcome of ASAS20 and ASAS40. All treatments with IL-17 and JAK inhibitors were generally safe and well tolerated. However, the two included netakimab clinical studies may have limitations. Therefore, the therapeutic agents should be carefully selected in clinical treatment. Moreover, the efficacy and safety of netakimab remain to be further analyzed in studies with larger sample sizes and longer follow-up times.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Lagom发布了新的文献求助10
刚刚
wyc发布了新的文献求助10
1秒前
科研通AI5应助Alara采纳,获得10
1秒前
3秒前
5秒前
CipherSage应助ewmmel采纳,获得10
6秒前
6秒前
Juan完成签到,获得积分10
6秒前
舟车靡从发布了新的文献求助10
7秒前
李健应助poletar采纳,获得10
8秒前
科目三应助向语堂采纳,获得10
9秒前
chorus发布了新的文献求助10
9秒前
wyc完成签到,获得积分10
9秒前
SMG发布了新的文献求助10
9秒前
科研通AI5应助heheha采纳,获得10
9秒前
Tu完成签到 ,获得积分10
10秒前
HBUCSS发布了新的文献求助10
11秒前
12秒前
12秒前
柚柚发布了新的文献求助10
12秒前
JamesPei应助priscilla采纳,获得10
12秒前
lzzk完成签到,获得积分10
13秒前
hym完成签到,获得积分10
13秒前
13秒前
Lagom完成签到,获得积分10
14秒前
英俊的铭应助阿珩采纳,获得10
14秒前
舟车靡从完成签到,获得积分10
14秒前
14秒前
奶油面包完成签到 ,获得积分10
15秒前
iedith018完成签到,获得积分10
15秒前
Cathy发布了新的文献求助10
15秒前
16秒前
16秒前
刘郁白完成签到,获得积分10
16秒前
17秒前
17秒前
17秒前
18秒前
可爱的函函应助Lagom采纳,获得10
18秒前
nlqwan完成签到,获得积分10
19秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Les Mantodea de Guyane Insecta, Polyneoptera 1000
Structural Load Modelling and Combination for Performance and Safety Evaluation 1000
Conference Record, IAS Annual Meeting 1977 820
England and the Discovery of America, 1481-1620 600
電気学会論文誌D(産業応用部門誌), 141 巻, 11 号 510
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3572963
求助须知:如何正确求助?哪些是违规求助? 3143128
关于积分的说明 9450156
捐赠科研通 2844589
什么是DOI,文献DOI怎么找? 1563562
邀请新用户注册赠送积分活动 731886
科研通“疑难数据库(出版商)”最低求助积分说明 718701